 |
Monica Heger tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb's In Sequence and Clinical Sequencing News. E-mail Monica Heger or follow her GenomeWeb Twitter accounts at @InSequence and @ClinSeqNews. |
Interpretation Remains Key Challenge in Clinical Sequencing; Patents May Impede Return of Results
June 27, 2012
Interpretation Remains Key Challenge in Clinical Sequencing; Patents May Impede Return of Results
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- ACMG Clarifies Without Changing Recommendations on Incidental Findings; Labs Begin to Adopt
May 8, 2013 / Clinical Sequencing News - New Products: Illumina's TruSight Tumor Content; Ambry's Tumor Profiling Services; More
April 10, 2013 / Clinical Sequencing News - After Pilot, Illumina Adds Clinical Interpretation as Option for Individual Genome Sequencing Service
November 28, 2012 / Clinical Sequencing News - Q&A: Illumina's Tina Hambuch on Clinical Whole-Genome Sequencing and CLIA Validation for NGS
April 25, 2012 / Clinical Sequencing News - Sequencing Breaks into the Clinic in 2011, but Ethical, Regulatory, and Technical Hurdles Remain
January 4, 2012 / Clinical Sequencing News